Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized comparison of field-directed treatments for actinic keratosis
NL-OMON50427Phase 4Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Dec 2014
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ingenol mebutate, fluorouracil, imiquimod and methyl aminolevulinate in actinic keratosis (AK) (4 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Treatment success at 12 months. Started Dec 2014; status: active, not recruiting.
02
Drugs
ingenol mebutatefluorouracilimiquimodmethyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NL-OMON50427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50427.